stockrowHUTCHMED (China) Limited Sponsored ADR (HCM) vs Xeris Biopharma Holdings, Inc. (XERS)
- HUTCHMED (China) Limited Sponsored ADR HCM 14.27 +2.51%
- Xeris Biopharma Holdings, Inc. XERS 12.95 +23.80%
HUTCHMED (China) Limited Sponsored ADR and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. HUTCHMED (China) Limited Sponsored ADR and Xeris Biopharma Holdings, Inc. are of similar size ($2.5B and $2.4B). HUTCHMED (China) Limited Sponsored ADR grew revenue faster over the last twelve months: 245.2% against 38.4%. Xeris Biopharma Holdings, Inc. has the higher net margin (−1.76% vs −23.6%) and the higher return on invested capital (27.2% vs 0.00%). Across the 17 metrics below, Xeris Biopharma Holdings, Inc. leads on 9 and HUTCHMED (China) Limited Sponsored ADR on 8.
Valuation
Profitability
| Metric | HCM | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 44.40% | 87.38% | 53.51% |
| Operating margin | 0.00% | 12.70% | 0.00% |
| Net margin | (23.63%) | (1.76%) | (2.45%) |
| Free cash flow margin | 0.00% | 20.00% | 0.00% |
| Return on equity | 0.00% | (27.11%) | (0.80%) |
| Return on assets | 0.00% | (1.64%) | (1.67%) |
| Return on invested capital | 0.00% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack